Puma Biotechnology Inc PBYI.OQ PBYI.O is expected to show a rise in quarterly revenue when it reports results on May 8 for the period ending March 31 2025
The Los Angeles California-based company is expected to report a 1.7% increase in revenue to $44.55 million from $43.8 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Puma Biotechnology Inc is for a loss of 2 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 20.8% in the last three months.
Wall Street's median 12-month price target for Puma Biotechnology Inc is $5.50, above its last closing price of $2.98.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | 0.11 | 0.10 | 0.39 | Beat | 279.9 |
Sep. 30 2024 | 0.34 | 0.35 | 0.41 | Beat | 16.9 |
Jun. 30 2024 | -0.13 | -0.13 | -0.09 | Beat | 30.6 |
Mar. 31 2024 | -0.22 | -0.22 | -0.10 | Beat | 53.8 |
Dec. 31 2023 | 0.32 | 0.30 | 0.26 | Missed | -13.2 |
Sep. 30 2023 | 0.08 | 0.08 | 0.12 | Beat | 56.5 |
Jun. 30 2023 | 0.01 | 0.01 | 0.05 | Beat | 566.7 |
Mar. 31 2023 | -0.07 | -0.07 | 0.03 | Beat | 142.9 |
This summary was machine generated May 6 at 22:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。